Friday, February 6, 2026 at 1:59 PM
Biogen anticipates a rise in profits due to its Alzheimer's drug Leqembi and cost-cutting measures, despite a projected decline in revenue from its multiple sclerosis treatments, which have seen significant sales drops.
Prices for GLP-1s are falling fast, forcing companies to adapt.
The pharma major said it faces the largest drug-patent expiry headwind in its history this year.
Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.
AbbVie posted higher fourth-quarter revenue on the back of growth from its immunology portfolio, led by arthritis and Crohn’s disease drugs Skyrizi and Rinvoq.
